A COVID-19 vaccine developed by the University of Oxford and AstraZeneca prevented a majority of people from getting the disease in a large trial, which is another promising development in the quest to end the pandemic. A rollout of the vaccine could begin next month.

The vaccine stopped an average of 70% of participants from falling ill, an early analysis of the data shows. The effectiveness rose to 90% for one of two regimens, using half a dose followed by a full one later, close to the high bar set by Pfizer and Moderna.

Astra and Oxford officials said they’re preparing to submit the findings to regulators and don’t expect the different outcomes in the study to affect the process. The U.S. could potentially take longer to sign off because a clinical trial will need more time before it delivers results.

“Our goal was to make sure we can have a vaccine that is accessible everywhere,” said Andrew Pollard, who is leading the Astra-Oxford trials. “I think we have actually managed to do that.”

The results, based on trials in the U.K. and Brazil, were reviewed after 131 participants contracted COVID-19. The full two doses showed an efficacy of 62%. Among those who received the vaccine, there were no severe cases and no participants were hospitalized. The group is planning to submit the data for peer review in the next 24 hours.

[vimeo 482789189 w=640 h=360]

AstraZeneca unveils another promising COVID-19 vaccine, following Pfizer and Moderna from Alabama NewsCenter on Vimeo.

Astra shares dropped as much as 2.2% in London, though they’ve risen about 30% since mid-March. Moderna and Pfizer shares surged when they reported their results.

AstraZeneca and Moderna vaccines are being tested at UAB.

The larger U.S. Astra trial, which could be key for approval here, has injected about 10,500 people with both doses. Mene Pangalos, Astra’s head of biopharma research, said the team is planning to talk to the U.S. Food and Drug Administration immediately and hopes to have another arm administering the half dose/full dose regimen starting within weeks.

“That scenario is possible,” he said. “We need to share the data with the FDA, which we will do very quickly, and then we will work out what the most appropriate steps are.”

 

Despite the apparently lower efficacy than shots from Pfizer and Moderna, which each prevented about 95% of cases, the British vaccine has some advantages. The shot can be kept at refrigerator temperatures, while those from Pfizer and Moderna, based on novel messenger RNA technology, require freezing for longer-term storage and transport. That would make Astra’s easier to deploy globally, particularly in lower- and middle-income countries. It also comes at a lower cost.

The Astra-Oxford team cautioned against comparing the efficacy levels of the vaccines too closely at this stage. Pam Cheng, who runs Astra’s global operations and is overseeing the manufacturing of the vaccine, said the half dose/full dose regimen shouldn’t affect global production or supplies of the shot, other than to potentially increase the number of doses available.

AstraZeneca expects to have more than 300 million doses ready to ship globally by the end of the first quarter of 2021, with about 100-200 million doses being produced monthly. For the U.K., the company expects to have up to 4 million doses ready by year-end, and 40 million by the end of the first quarter of 2021.

The differing results of the two regimens may leave questions about the best way to give the AstraZeneca shot. Analysts at Barclays had put consensus expectations at 70% to 90% for what would be deemed a success from AstraZeneca, following conversations with investors in Europe and the U.S.

AstraZeneca said it will immediately prepare to submit data to authorities around the world that have a framework in place for early approval. The company said it will seek emergency-use listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries.

Vaccine developers will not know how long any protection lasts for a number of months as they monitor antibody levels to see how quickly they fade. U.K. and European Union regulators are conducting accelerated reviews of the results from both Astra and Pfizer, which has applied for an emergency use authorization in the U.S.

Astra and Oxford have been among the fastest-moving vaccine developers. After years spent working on a vaccine against Middle East Respiratory Syndrome, which is related to COVID-19, Oxford’s scientists had an advantage that allowed them to move quickly to create a shot.

“I have little doubt that this vaccine is going to have a big impact globally,” Astra’s Pangalos said.

Marthe Fourcade assisted in this report.